Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough

Stock Track

Apr 17, 2025

Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.

BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.

Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181488210"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181488210\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181488210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181488210","market":"sg","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-17 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1181488210","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181488210","pubTimestamp":1744895823,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S  shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"由于分析师下调评级和竞争对手的突破，诺和诺德股价盘前暴跌7.57%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.\nBMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.\nAdding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}